SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to a published research paper highlighting its APU's potential to match GPU-level AI performance with significantly less energy consumption, sparking discussions about its disruptive potential in the AI infrastructure market. Community members are actively debating whether this news positions GSIT as a long-term player against giants like NVIDIA or if it's a short-lived hype, while also speculating about potential buyouts. The stock's surge has attracted both bullish investors and short-sellers, leading to high trading volume and price volatility.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics Inc. is trending as investors anticipate the unveiling of their new AI-powered robot at the upcoming NVIDIA GTC conference, fueling speculation about potential partnerships and advancements in automation. Community discussions revolve around the stock's high short interest and potential for a violent run, with some noting Blackrock's increased share as a positive signal. Others are weighing the company's future prospects against its current market capitalization and revenue.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending as investors eagerly anticipate upcoming earnings, fueled by a recent strategic investment and growing optimism around its AI data center initiatives. The community is closely watching for updates on the Helios project and potential ERCOT approvals, with many expressing bullish sentiment and speculating about a significant price surge. Discussions also include Galaxy Digital's diversified revenue streams, particularly its digital asset platform, and its potential to outperform competitors in the long term.

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Elevance Health Inc

Elevance Health is trending as investors monitor the potential impact of upcoming earnings and broader sector headwinds. Community members are weighing whether the recent pullback represents a value opportunity or a sign of further struggles, drawing comparisons to competitors like UnitedHealth and Humana. Discussions also involve speculation about potential government intervention and adjustments to ACA subsidies.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group ($UNH) is trending as investors discuss the potential impacts of competitor earnings, a possible resolution to the government shutdown, and related ACA subsidies. Community members are weighing the influence of institutional investors like Warren Buffett, while others debate the significance of ongoing DOJ investigations and their potential effects on the stock's price. Bullish sentiment anticipates a run to $400, while bears foresee a tumble after earnings, creating a tense atmosphere as traders position themselves.

Solid Power, Inc. engages in the manufacture and supply of power batteries. The firm develops all solid state battery cell technology that replaces the liquid or gel polymer electrolyte used in conventional lithium-ion battery cells with a sulfide-based solid electrolyte. It focuses on the development and commercialization of all solid state battery cells and solid electrolyte materials, primarily for the battery-powered electric vehicle market. The company was founded on August 3, 2011 and is headquartered in Louisville, CO.

Solid Power Inc

Solid Power Inc - Ordinary Shares - Class A

Solid Power ($SLDP) is trending amid increasing investor confidence in solid-state battery technology and strategic partnerships with BMW and SK On. Community discussions highlight the potential for safer, higher-energy-density batteries, drawing comparisons to other battery stocks. Many are closely watching for news from upcoming BMW conferences, anticipating a positive catalyst for further gains.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group (REPL) is trending as investors discuss the potential impact of a resubmitted application for its melanoma treatment after previously facing rejection; the FDA acceptance news has sparked both optimism and skepticism. Community members are debating potential short squeezes, upcoming catalysts, and revised price targets, with some cautioning about possible dilution or a pullback. The stock's volatile price action and the broader implications for the biotech sector are also being closely monitored.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge, driven by a potential supply squeeze and increased industrial demand; some community members are discussing possible price manipulation and advocating for physical silver investments instead of the ETF. Bullish sentiment is fueled by expectations of continued price increases, while others caution about overbought conditions and potential pullbacks, noting silver's historical volatility relative to gold.

AlphaVest Acquisition Corp. is a blank check company, which engages in effecting a merger, stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded on January 14, 2022 and is headquartered in New York, NY.

AlphaVest Acquisition Corp

AlphaVest Acquisition Corp ($ATMV) is trending due to discussions around a potential short squeeze and high volatility. The community is actively watching for breakouts, particularly above the $16 level, while also noting the stock's low float and potential for rapid price movements. Some traders are also speculating about news related to a merger.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is trending due to a failed phase 3 trial for its anxiety medication, causing a significant drop in share price and sparking a debate about whether it's an overreaction. The community is weighing the company's cash runway, partnership with Merck for an Alzheimer's drug, and potential for a bounce, with some seeing a buying opportunity while others express concern about the missed endpoints.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to...

BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX

ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.

Teladoc Health Expands Clarity Platform With Workplace Safety Tool

TDOC enhances its Clarity platform with an AI-driven tool to help hospitals combat rising workplace violence incidents.

RBC Capital, Jefferies, and TD Cowen raised their price targets on BioCryst after the company announced plans to acquire Astria Therapeutics in a $700 million deal, with analysts calling the sell-off overdone and the combination strategically sound.<a href="https://stocktwits.com/symbol/BCRX">BioCryst shares</a> fell 8.8% to $6.42 on Tuesday, marking their fourth straight session of losses and the biggest single-day drop in nearly eight months, before edging up 1% in after-hours trading.Meanwhile,&nbsp;<a href="https://stocktwits.com/symbol/ATXS">Astria Therapeutics’ stock</a> jumped 37.1% to $11.61 on Tuesday, its best day in nearly five years and highest level in almost a year, extending gains for a second straight session.RBC Capital raised its price target on BioCryst Pharmaceuticals to $15 from $14 and kept an 'Outperform' rating, saying Tuesday’s weakness in the stock presents a “compelling buying opportunity.” The firm said its confidence increased following BioCryst’s acquisition of Astria Therapeutics and discussions with management, adding that the deal sets up their franchise even better.Jefferies also raised its target on BioCryst to $15 from $14 while maintaining a 'Buy' rating. Analyst Maury Raycroft said the valuation reflects a discount due to a crowded hereditary angioedema (HAE) landscape, potential clinical and regulatory risks, and the need for FTC clearance, but added that the acquisition structure, under which Astria shareholders will own about 15% of the combined company, makes competing bids less likely.Meanwhile, TD Cowen reinstated coverage of BioCryst with a 'Buy' rating and a $30 price target, citing the company’s plan to acquire Astria’s Phase 3 injectable HAE prophylaxis candidate navenibart. The firm said navenibart, a plasma kallikrein inhibitor with strong proof of concept and high key opinion leader interest, is “de-risked.”&nbsp;BioCryst said on Tuesday that it will acquire Astria for $13 per share, valuing the company at about $700 million in enterprise value. The transaction, approved by both boards, is expected to close in the first quarter of 2026. BioCryst will finance the $8.55-per-share cash portion through a mix of existing cash and a new $550 million facility from Blackstone, with the rest paid in BioCryst stock.Astria’s navenibart, designed for quarterly or semi-annual injections, could expand BioCryst’s reach in the HAE market by complementing its existing oral therapy. BioCryst CEO Jon Stonehouse said the deal enables the company to “build out a comprehensive portfolio” that meets patient needs regardless of treatment preference.On Stocktwits, retail sentiment for both BioCryst and Astria was ‘extremely bullish’ amid ‘extremely high’ message volume.One bullish user said they had grown more positive on the Astria deal, noting that if the acquired asset is approved, it could make BioCryst’s revenue growth sustainable for years, which would help the company’s valuation even if some concerns remain.<stembedurl>https://stocktwits.com/luvpizza2/message/632344600</stembedurl>Another bullish user said the stock’s performance looked solid despite dilution, arguing that using undervalued shares to acquire a high-potential growth asset like Astria was a smart strategic move and could significantly boost BioCryst’s long-term worth.<stembedurl>https://stocktwits.com/Uptrending21/message/632308543</stembedurl>While BioCryst’s stock has declined 15% so far in 2025, Astria’s stock has risen 30% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

While BioCryst’s stock (BCRX) has declined 15% so far in 2025, Astria’s stock (ATXS) has risen 30% over the same period. (Photo credit: Getty Images)

BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play

The deal, valued at $700 million and backed by new Blackstone financing, is expected to close in early 2026.

Equity

Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock?

Investors need to pay close attention to BCRX stock based on the movements in the options market lately.

BioCryst Pharmaceuticals Inc. (BCRX) announced on Tuesday that it has struck a definitive deal to acquire Astria Therapeutics Inc.(ATXS), a clinical-stage biotech firm developing treatments for rare allergic and immunologic conditions.&nbsp;The agreement values Astria at $13.00 per share, totaling approximately $700 million in enterprise value. The acquisition, approved unanimously by both companies’ boards, is expected to close in the first quarter of 2026.To support the acquisition, BioCryst will fund the $8.55-per-share cash portion through a mix of cash on hand and a new financing facility from Blackstone, which offers up to $550 million in capital. The remainder of the consideration will be paid in BioCryst stock. Astria shareholders will own about 15% of the combined entity upon close.<a href="https://stocktwits.com/symbol/BCRX">BioCryst Pharmaceuticals’ stock</a> traded over 8% lower in Tuesday’s premarket.&nbsp;Astria’s flagship asset, navenibart, is a long-acting monoclonal antibody designed to prevent hereditary angioedema (HAE) attacks. Currently in Phase 3 trials, it offers a potential shift in care with its quarterly or semi-annual injection schedule. BioCryst aims to integrate navenibart alongside its existing oral therapy for HAE, creating a complementary treatment offering.“We believe this transaction gives BioCryst a perfect second product candidate that fits seamlessly with our HAE core competency and enables us to build out a comprehensive portfolio that could offer the most patient-friendly option, regardless of administration preference,” said CEO&nbsp; of BioCryst, Jon Stonehouse. “Navenibart can emerge as the injectable of choice for patients seeking infrequent, pain-free dosing, strong attack control, and a mechanism of action they know and understand.”The deal gives BioCryst access to a market of roughly 5,000 patients in the U.S. who currently rely on injectable prophylaxis.&nbsp;BioCryst Pharmaceuticals’ stock has lost over 5% in the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uuuu-stock-on-track-to-hit-14-year-highs-as-critical-minerals-sector-continues-to-see-strong-investor-interest/ch6mn1qR3mJ">UUUU Stock On Track To Hit 14-Year Highs As Critical Minerals Sector Continues To See Strong Investor Interest</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of the biopharmaceutical company Curevac.

BioCryst To Acquire Astria Therapeutics In $700M Deal

The agreement values Astria at $13.00 per share, totaling approximately $700 million in enterprise value.

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that the companies have entered into a definitive agreement under which BioCryst has agreed...

Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround 

BioCryst (BCRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Are Options Traders Betting on a Big Move in BCRX Stock?

Investors need to pay close attention to BioCryst Pharmaceuticals stock based on the movements in the options market lately.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BCRX News

BCRXBiocryst Pharmaceuticals Inc.